{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:21:14Z","timestamp":1783621274728,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.amjcard.2026.05.009","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:41:44Z","timestamp":1778600504000},"page":"68-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Mortality and Heart Failure Hospitalization in Patients With HFpEF on Mineralocorticoid Receptor Antagonists: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9291-7812","authenticated-orcid":false,"given":"Marc","family":"Knezevic-Maragh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Gilani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nair Anandita","family":"Nandakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdur Rahmaan MY","family":"Hudli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Puhachova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wajiha","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Park","family":"Esther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"AlGhaithi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadhra","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Bengherbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2026.05.009_bib0001","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","article-title":"A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000\u20132010","volume":"175","author":"Gerber","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0002","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1161\/CIRCRESAHA.115.302922","article-title":"Heart failure with preserved ejection fraction","volume":"115","author":"Sharma","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0003","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ejhf.483","article-title":"Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review","volume":"18","author":"Van Riet","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0004","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jchf.2022.01.018","article-title":"Atrial fibrillation in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"10","author":"Cikes","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0005","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.hrthm.2016.03.003","article-title":"Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: characteristics and prognostic implications","volume":"13","author":"Siontis","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0006","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0007","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0008","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0009","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40256-019-00353-5","article-title":"Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: a post hoc analysis of the randomized placebo-controlled TOPCAT trial","volume":"20","author":"Neefs","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0010","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.012437","article-title":"Finerenone improves outcomes in patients with heart failure with mildly reduced or preserved ejection fraction irrespective of age: a prespecified analysis of FINEARTS-HF","volume":"17","author":"Chimura","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0011","doi-asserted-by":"crossref","DOI":"10.15420\/cfr.2025.28","article-title":"Cardiovascular benefits of spironolactone in heart failure with mildly reduced or preserved ejection fraction: insights from a win ratio analysis of the TOPCAT trial","volume":"11","author":"Nguyen","year":"2025","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.03.041","article-title":"Efficacy and safety of finerenone in heart failure with preserved ejection fraction: a FINE-HEART analysis","volume":"13","author":"Ostrominski","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0013","doi-asserted-by":"crossref","DOI":"10.18549\/PharmPract.2019.1.1376","article-title":"Evaluation of aldosterone antagonist utilization in heart failure with reduced and preserved ejection fraction at an academic medical center","volume":"17","author":"Bradley","year":"2019","journal-title":"Pharmacy Practice"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0014","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006540","article-title":"Use of mineralocorticoid receptor antagonists in patients with heart failure with preserved ejection fraction","volume":"6","author":"Cooper","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0015","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s00228-021-03153-6","article-title":"Prognostic association of medication trajectories with 3-year mortality in heart failure with preserved ejection fraction: findings from the EPICAL2 cohort study","volume":"77","author":"Bitar","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0016","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0017","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jchf.2012.08.001","article-title":"Aldosterone antagonists and outcomes in real-world older patients with heart failure with preserved ejection fraction","volume":"1","author":"Patel","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0018","first-page":"1165","article-title":"Risk stratification and efficacy of spironolactone in patients with heart failure with preserved ejection fraction: secondary analysis of the TOPCAT randomized clinical trial","volume":"35","author":"Lin","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0019","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jchf.2019.01.003","article-title":"Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a TOPCAT trial analysis","volume":"7","author":"Merrill","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0020","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1002\/ehf2.12867","article-title":"Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction","volume":"7","author":"Suzuki","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0021","first-page":"856","article-title":"Spironolactone in patients with permanent atrial fibrillation and preserved ejection fraction (IMPRESS-AF): a randomized controlled trial","volume":"41","author":"Shantsila","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0022","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cardfail.2018.03.002","article-title":"Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial","volume":"24","author":"Desai","year":"2018","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0023","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1161\/CIRCHEARTFAILURE.115.002249","article-title":"Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone","volume":"8","author":"Shah","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0024","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004457","article-title":"Racial differences in characteristics and outcomes of patients with heart failure with preserved ejection fraction in the treatment of preserved cardiac function heart failure trial","volume":"11","author":"Lewis","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0025","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ahj.2024.02.021","article-title":"Previous heart failure hospitalization, spironolactone, and outcomes in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT","volume":"271","author":"Szabo","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0026","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011521","article-title":"Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction","volume":"9","author":"McDiarmid","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2026.05.009_bib0027","article-title":"Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease: balance of efficacy and risk","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926003413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926003413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:01:10Z","timestamp":1783620070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914926003413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"alternative-id":["S0002914926003413"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.05.009","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mortality and Heart Failure Hospitalization in Patients With HFpEF on Mineralocorticoid Receptor Antagonists: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}